On Thursday, Marriott International Inc (NASDAQ:MAR)’s shares declined -0.27% to $76.17.
Marriott International Inc (MAR) the world’s favorite travel company, and Universal Music Group (UMG), the global music leader, have created a first-of-its-kind global marketing partnership that will comprise exclusive performances by established and emerging recording artists, branded video series, social content, music downloads, ticket offers and more. The partnership joins Marriott International’s 19 brands, counting The Ritz-Carlton, EDITION, JW Marriott, Renaissance and Marriott Hotels, with illustrious UMG music labels such as Capitol Music Group, Def Jam Recordings, Interscope Geffen A&M, Island Records, Republic Records and UMG Nashville.
Marriott and UMG are setting out to engage a new generation of experience-seekers, travelers and music fans to deliver unique #WithTheBand experiences. Starting this summer, the partnership will premiere live performances for hotel guests at select properties across Marriott International’s portfolio of brands around the globe. On June 30, 2015, the St. Pancras Renaissance London Hotel will feature a live performance by pop sensation and ‘The Voice Australia’ judge, Jessie J, kicking off a series of exclusive, on-property performances on five different continents.
Marriott International, Inc. operates, franchises, and licenses hotels and timeshare properties worldwide. It operates through three segments: North American Full-Service, North American Limited-Service, and International. The company also licenses the development, operation, marketing, sale, and administration of vacation ownership and related products under the Marriott Vacation Club, Grand Residences by Marriott, The Ritz-Carlton Destination Club, and The Ritz-Carlton Residences brands to the Marriott Vacations Worldwide Corporation.
Nuance Communications Inc. (NASDAQ:NUAN)’s shares dropped -0.99% to $18.09.
Nuance Communications Inc. (NUAN) declared a partnership with Jvion, a healthcare predictive analytics company, to provide further support to healthcare organizations with Advanced Practice Clinical Documentation Improvement™ (CDI) as they prepare for the shift to a value-based reimbursement model. Part of the Nuance Clintegrity 360 solution, Advanced Practice CDI now provides physicians with real-time visibility and guidance into how clinical documentation translates into quality metric scores and appropriate reimbursement. By counting Jvion’s data analytics reports into Advanced Practice CDI, Nuance enables organizations to dive deeper into their own clinical data and pinpoint specific target areas for clinical documentation improvement.
Although the industry is transitioning payment models, many healthcare organizations are not prepared to fully make this shift due to the revenue gap that exists between reimbursement under recently’s fee-for-service system and the changing rules under a value-based payment model. Advanced Practice CDI arms healthcare organizations with actionable insights and data to ensure they are accurately and comprising charting information to capture the severity of their patient populations, case mix index (CMI) and associated levels of care.
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers hosted and on-premise solutions and services that provide platforms to generate and distribute clinical documentation through the use of dictation and transcription features; clinical documentation improvement programs; and speech recognition solutions for radiology, cardiology, pathology, and related specialties enabling healthcare providers to dictate, edit, and sign reports without manual transcription. The company also offers mobile and consumer solutions comprising voice control and text-to-speech solutions; dictation applications; text input; mobile messaging services; and Web search and voicemail-to-text services for use in phones, cars, tablets, desktop and portable computers, televisions, smart watches, personal navigation devices, and other consumer electronics.
At the end of Thursday’s trade, Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s shares surged 0.81% to $13.66.
Amicus Therapeutics, Inc. (FOLD) was a big mover last session with its shares rising nearly 8% on the day. The upside was owing to the company’s pricing of an underwritten offering of 16,981,132 shares of its common stock at $13.25 per share. The gross proceeds from the offering are predictable to be $225 million. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,547,170 shares of its common stock. This led to far more shares changing hands than in a normal session. The move continues the recent uptrend for the company, as the stock has gained over 37% in the past one-month time frame.
This biopharmaceutical company has seen no estimate revisions in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same time frame. Friday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs comprise next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I. It also develops pharmacological chaperone migalastat HCl as a monotherapy that has accomplished two Phase III global registration studies for Fabry disease; ATB200, a recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for the treatment of Parkinson’s disease.
Transition Therapeutics Inc (USA) (NASDAQ:TTHI), ended its Thursday’s trading session with 7.66% gain, and closed at $2.53.
Transition Therapeutics Inc (USA) (TTHI) declared that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) and the Centralized Procedure has begun for the oral small molecule pharmacological chaperone Galafold (migalastat HCl) for Fabry patients who have amenable genetic mutations. As previously announced, Galafold is the first investigational Fabry drug to be granted Accelerated Assessment in the EU. In the U.S., Amicus plans to conduct a pre-NDA meeting with the FDA and to submit a New Drug Application (NDA) for Galafold under Subpart H1 in the second half of 2015. Following the MAA validation, Amicus is also initiating the regulatory submission process in several additional geographies.
Transition Therapeutics Inc., a biopharmaceutical company, researches and develops therapeutic agents for disease indications in Canada. The company’s lead central nervous system drug candidate is ELND005, a Phase II clinical trial product used for the treatment of agitation/aggression associated with Alzheimer’s disease and Down syndrome; and lead metabolic drug candidate is TT401, a Phase II clinical study for the treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics Inc. has a licensing and collaboration agreement with Eli Lilly to develop and commercialize rights to type 2 diabetes drug candidate TT401. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. in December 2000. Transition Therapeutics Inc. was founded in 1987 and is headquartered in Toronto, Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
